{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:59:11Z","timestamp":1770825551840,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T00:00:00Z","timestamp":1438819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T00:00:00Z","timestamp":1438819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HORM CANC"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s12672-015-0233-2","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T13:10:25Z","timestamp":1438780225000},"page":"254-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Symptomatic Control of Neuroendocrine Tumours with Everolimus"],"prefix":"10.1007","volume":"6","author":[{"given":"Hannah E.","family":"Bainbridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Larbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,6]]},"reference":[{"key":"233_CR1","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC EYao","year":"2008","unstructured":"EYao JC, Hassan M, Phan A et al (2008) One hundred years after \u2018carcinoid\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063\u20133072","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"233_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10555-011-9292-1","volume":"30","author":"K Oberg","year":"2011","unstructured":"Oberg K, Castellano D (2011) Current knowledge on diagnosis and staging of neuroendocrine tumours. Cancer Metastasis Rev 30(Suppl 1):3\u20137","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"233_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11136-009-9487-x","volume":"18","author":"T Haugland","year":"2009","unstructured":"Haugland T, Vatn MH, Veenstra M, Wahl AK, Natvig GK (2009) Health related quality of life in patients with neuroendocrine tumours compared with the general Norwegian population. Qual Life Res 18(6):719\u2013726","journal-title":"Qual Life Res"},{"key":"233_CR4","doi-asserted-by":"crossref","unstructured":"Fr\u00f6jd C, Larsson G, Lampic C, von Essen L (2007) Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 5:18","DOI":"10.1186\/1477-7525-5-18"},{"issue":"3","key":"233_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"JL Beaumont","year":"2012","unstructured":"Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC (2012) Comparison of health-related quality of life in patients with neuroendocrine tumours with quality of life in the general US population. Pancreas 41(3):461\u2013466","journal-title":"Pancreas"},{"key":"233_CR6","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656\u20134663","journal-title":"J Clin Oncol"},{"key":"233_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikta JB et al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumours. N Engl J Med 371:224\u2013233","journal-title":"N Engl J Med"},{"key":"233_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69\u201376","journal-title":"J Clin Oncol"},{"key":"233_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514\u2013523","journal-title":"N Engl J Med"},{"issue":"9808","key":"233_CR10","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005\u20132012","journal-title":"Lancet"},{"issue":"1","key":"233_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/annonc\/mdq670","volume":"22","author":"J Capdevila","year":"2011","unstructured":"Capdevila J, Diez Miranda I, Obiols G, Tabernero J (2011) Control of carcinoid syndrome with everolimus. Ann Oncol 22(1):237\u2013239","journal-title":"Ann Oncol"},{"issue":"3","key":"233_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1023\/A:1026458604826","volume":"6","author":"RJ Stephens","year":"1997","unstructured":"Stephens RJ, Hopwood P, Girling DJ, Machin D (1997) Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 6(3):225\u201336","journal-title":"Qual Life Res"},{"issue":"17","key":"233_CR13","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","volume":"22","author":"EK Fromme","year":"2004","unstructured":"Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22(17):3485\u20133490","journal-title":"J Clin Oncol"}],"container-title":["Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-015-0233-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12672-015-0233-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-015-0233-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-015-0233-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T17:47:59Z","timestamp":1609264079000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12672-015-0233-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,6]]},"references-count":13,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["233"],"URL":"https:\/\/doi.org\/10.1007\/s12672-015-0233-2","relation":{},"ISSN":["1868-8497","1868-8500"],"issn-type":[{"value":"1868-8497","type":"print"},{"value":"1868-8500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,6]]},"assertion":[{"value":"27 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}